Welcome to our dedicated page for Chain Bridge I SEC filings (Ticker: CBRGU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trust account balances, redemption deadlines, and sponsor warrants make Chain Bridge I’s disclosures uniquely challenging. If you have ever opened a 300-page de-SPAC proxy and wondered where the dilution math hides, you are not alone. Our platform solves that problem by converting dense SEC language into plain English the moment each document hits EDGAR.
Stock Titan’s AI-powered summaries highlight what matters in every filing type:
- Form 4 alerts track Chain Bridge I insider trading Form 4 transactions and provide Chain Bridge I Form 4 insider transactions real-time so you can see sponsor moves before redemption dates.
- 10-Q and 10-K snapshots reveal trust interest income and operating burn, delivering a concise Chain Bridge I quarterly earnings report 10-Q filing and a Chain Bridge I annual report 10-K simplified.
- 8-Ks flag merger announcements, extension votes, and other material events, giving you Chain Bridge I 8-K material events explained without wading through legalese.
- Proxy & S-4 documents outline the deal terms and Chain Bridge I proxy statement executive compensation, letting you model post-merger ownership in minutes.
Whether you are arbitraging warrants, monitoring redemption pressure, or preparing for the vote, our AI answers the questions you actually ask: “How much dilution will the PIPE create?” and “What did the sponsor pay for promote shares?” With Chain Bridge I SEC filings explained simply, you can focus on decisions, not document hunting.
Use cases include:
- Comparing trust value against redemption price with Chain Bridge I earnings report filing analysis
- Tracking Chain Bridge I executive stock transactions Form 4 before key announcements
- Quickly understanding Chain Bridge I SEC documents with AI when a merger target is revealed
Real-time updates, expert commentary, and clean dashboards mean you never miss an opportunity buried in the fine print.
BriaCell Therapeutics Corp. is conducting a best-efforts public offering of 10,775,000 Common Units at $1.25 each and up to 1,225,000 Pre-Funded Units at $1.249. Each Unit delivers one post-consolidation common share plus a five-year warrant exercisable at $1.50. The securities, as well as the 12.0 million warrants and 1.225 million pre-funded warrants issuable, will not be listed. ThinkEquity is placement agent and will receive a 7.5% cash fee ($0.09375/unit).
Assuming full subscription, gross proceeds equal $15.0 million; net proceeds are estimated at $13.4 million. Pro-forma cash would rise to roughly $25.9 million, while shareholders’ equity increases to $25.4 million (as of 30 Apr 2025). Funds are earmarked for working capital and advancement of BriaCell’s oncology pipeline, including the Fast-Track Phase 3 Bria-IMT study in metastatic breast cancer.
The transaction is highly dilutive: shares outstanding jump from 6.8 million to 18.8 million on conversion of the pre-funded warrants, before any warrant exercises. No minimum raise or escrow is required, so partial closings could leave the firm with less cash and investors without refund rights. Risk factors also cite recurring losses (YTD net loss $18.4 million), Nasdaq listing compliance history, and the absence of a trading market for the offered warrants.
Chain Bridge I (Commission File No. 001-41047) has filed its Form 10-K for the year ended 31 December 2024. The Cayman Islands-incorporated SPAC remains a non-accelerated filer, smaller reporting company and emerging growth company. It affirms that all required Exchange Act reports and Interactive Data Files were filed on time during the past 12 months.
- Shell status: The registrant continues to be a shell company pending completion of an initial business combination.
- Market value: On 30 June 2024, the market value of non-affiliate ordinary shares was $11.28 million based on a closing price of $11.21.
- Securities: Units (CBGGF), Class A shares (CBRRF) and warrants (CBRGF) are quoted on OTC Markets; each unit contains one Class A share and one-half warrant.
- Capital structure as of 16 June 2025: 29,707 units, 3,014,736 Class A shares, 3,191,000 Class B shares and 22,035,138 warrants outstanding.
- Financing arrangements: A forward purchase agreement with Franklin Strategic Series provides for the sale of 4 million Class A shares and 2 million warrants for $40 million, to close concurrently with the future business combination.
- Controls & compliance: No auditor attestation under SOX 404(b) is required; no error-correction restatements or clawback analyses are indicated.
No revenue, earnings or cash-flow data are presented in the excerpt, and the filing discloses no completed business combination to date.
FAQ
What is the current stock price of Chain Bridge I (CBRGU)?
What is Chain Bridge I Units (CBRGU)?
What is the purpose of Chain Bridge I Units?
How does Chain Bridge I Units operate?
What is the symbol for Chain Bridge I Units?
What industries does Chain Bridge I Units target?
What are the recent achievements of Chain Bridge I Units?
What sets Chain Bridge I Units apart from other companies?
How does Chain Bridge I Units benefit shareholders?
What is the current financial condition of Chain Bridge I Units?
What is the primary goal of Chain Bridge I Units?
